Your browser is no longer supported. Please, upgrade your browser.
We’ve released a new Beta version of our Futures section! Try it now. We look forward to your feedback! ×
Settings
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E33.88 EPS (ttm)12.38 Insider Own0.10% Shs Outstand234.61M Perf Week-1.46%
Market Cap98.40B Forward P/E21.02 EPS next Y19.95 Insider Trans-22.45% Shs Float234.43M Perf Month-1.98%
Income2.93B PEG1.92 EPS next Q3.91 Inst Own92.50% Short Float1.19% Perf Quarter23.41%
Sales9.70B P/S10.14 EPS this Y58.40% Inst Trans0.27% Short Ratio1.50 Perf Half Y37.21%
Book/sh45.90 P/B9.14 EPS next Y17.53% ROA22.10% Target Price480.67 Perf Year43.90%
Cash/sh7.87 P/C53.32 EPS next 5Y17.64% ROE29.40% 52W Range275.39 - 480.18 Perf YTD23.56%
Dividend- P/FCF37.07 EPS past 5Y29.90% ROI26.20% 52W High-12.65% Beta1.05
Dividend %- Quick Ratio1.70 Sales past 5Y17.30% Gross Margin87.90% 52W Low52.31% ATR11.33
Employees7550 Current Ratio2.10 Sales Q/Q34.30% Oper. Margin40.40% RSI (14)47.53 Volatility1.99% 2.63%
OptionableYes Debt/Eq0.05 EPS Q/Q94.80% Profit Margin30.20% Rel Volume0.99 Prev Close428.65
ShortableYes LT Debt/Eq0.05 EarningsApr 24 BMO Payout0.00% Avg Volume1.85M Price419.44
Recom2.00 SMA20-2.60% SMA500.59% SMA20019.00% Volume1,834,376 Change-2.15%
Mar-23-15Downgrade Stifel Buy → Hold
Feb-02-15Reiterated Argus Buy $385 → $440
Jan-30-15Reiterated RBC Capital Mkts Outperform $400 → $445
Jan-30-15Reiterated Deutsche Bank Buy $430 → $460
Oct-22-14Upgrade Robert W. Baird Neutral → Outperform $374 → $382
Aug-19-14Resumed Stifel Buy $376
Jul-29-14Reiterated Argus Buy $360 → $385
Jul-24-14Reiterated UBS Neutral $330 → $354
Jul-09-14Reiterated RBC Capital Mkts Outperform $325 → $375
Mar-19-14Reiterated Stifel Buy $360 → $376
Mar-07-14Reiterated Barclays Overweight $325 → $352
Mar-03-14Reiterated Stifel Buy $330 → $360
Jan-30-14Reiterated UBS Neutral $300 → $310
Jan-30-14Reiterated Brean Capital Buy $293 → $377
Jan-30-14Reiterated Argus Buy $310 → $360
Jan-28-14Reiterated Deutsche Bank Buy $340 → $415
Jan-27-14Reiterated Canaccord Genuity Buy $291 → $355
Jan-16-14Reiterated Stifel Buy $296 → $321
Jan-10-14Reiterated Barclays Overweight $285 → $325
Dec-20-13Reiterated RBC Capital Mkts Outperform $275 → $325
Apr-18-15 08:02AM  Meet 4 IBD 50 Companies Reporting Earnings This Week at Investor's Business Daily
12:01AM  Two Styles, One Vision at Barrons.com
Apr-17-15 04:53PM  Biotech Investors Shouldn't Miss These Stocks This Earnings - Earnings ESP
04:31PM  It's A Big Weekend For Biotech
01:44PM  Biotech investors brace for updates on key drugs at CNBC
01:17PM  FDA approves generic version of top-selling MS drug Copaxone
01:05PM  Why These May Be the Top 4 Growth Stocks of 2015 at Investopedia
04:00AM  French firm's drug succeeds in pivotal trial for progressive MS
Apr-16-15 06:16PM  VIVUS Responds to Teva's Filing for Qsymia Generics - Analyst Blog
06:14PM  AbbVie's HCV Treatment Granted Priority Review in Japan - Analyst Blog
05:26PM  Biotech giants present new data
10:50AM  Receptos MS Drug Succeeds Against Ulcerative Colitis at Investor's Business Daily
09:30AM  The Zacks Analyst Blog Highlights: Medicines Co., Tekmira, GW Pharmaceuticals, Biogen and Alexion - Press Releases
09:00AM  Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day PR Newswire
08:44AM  Synta Pharmaceuticals (SNTA) Catches Eye: Stock Jumps 10.7% - Tale of the Tape
Apr-15-15 06:10PM  Biogen Reports New Data from Acute Optic Neuritis Study - Analyst Blog
04:03PM  Read these books to become a better trader/investor
03:15PM  Biotech Stock Roundup: Favorable Briefing Documents for MDCO's Kengreal, Alexion Soliris Label Update - Analyst Blog
11:49AM  Pfizer, Biogen, AbbVie Get Good Drug-Trial News at Investor's Business Daily
09:08AM  Morning Movers: Delta Air Lines Soars on Earnings; Biogen Jumps on Trial Data at Barrons.com
09:04AM  Stock Futures Grapple Higher; Biogen, Akorn Lead IBD 50 List at Investor's Business Daily
08:48AM  What Were Trading
Apr-14-15 10:46PM  Biogen Earnings Preview: 3 Key Factors to Monitor at Investopedia
08:03PM  GoPro, Avon and Intel Highlight Tuesday's After-Hours Movers
04:59PM  Tuesday's after-hours buzz: Intel, Biogen & more at CNBC
04:45PM  Alnylam Reports Publication of New Data on Hemophilia Drug - Analyst Blog
04:05PM  Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair Business Wire
04:00PM  Biogen MS Drug Results Are 'Mildly Encouraging' In Eye Disease Test at Forbes
01:40PM  Aeterna Zentaris to Advance Hormone Drug to Phase III Study - Analyst Blog
11:22AM  U.S. Patent Office Declares an Interference Between Forward Pharma and Biogen Regarding the Treatment of Multiple Sclerosis With 480 mg Daily Dose of DMF, the Active Ingredient in Tecfidera(R) GlobeNewswire
10:45AM  J&J Beats on Q1 Earnings, Cuts View on Currency Woes - Analyst Blog
10:11AM  Receptos Inc (RCPT), Centene Corp (CNC): Paul Sinclair Flying High With New Funds Top Healthcare Picks at Insider Monkey
12:10AM  Growth In Drug Spend Is Hitting A 13-Year High. Note To Pharma: Innovation Pays. at Forbes
12:00AM  U.S. prescription drug spending rose 13 pct in 2014-IMS report
Apr-13-15 09:10PM  Should Biogen Be Afraid of This Upstart? at Investopedia
11:00AM  Will Pharmaceutical Sales Drive J&J (JNJ) Earnings Again? - Analyst Blog
09:30AM  Biogen, SodaStream, TASER International, Napco Security Technologies and SuperCom highlighted as Zacks Bull and Bear of the Day - Press Releases
08:35AM  Short Sellers Increase Their Bets Against Biotech Stocks at 24/7 Wall St.
07:30AM  Bull of the Day: Biogen (BIIB) - Bull of the Day
Apr-10-15 02:36PM  Here are 10 local biotechs investing heavily in their future at bizjournals.com
12:13PM  Why Eisai layoffs won't pack as big a punch in Research Triangle Park at bizjournals.com
07:00AM  Why do drugs have such weird names? at CNBC
02:00AM  Eisai Drops On US Job Cuts, Still A Stunning Run On Alzheimer's Drug With Biogen at Barrons.com
Apr-09-15 07:36PM  5 biotech bets: Trading a surging sector at CNBC
06:11PM  Biogen Goes Generic at Investopedia
05:00PM  5 biotech bets: Large & small
12:20PM  Biogen Investors: Active Ingredient In Patient Death Is Not Changing BofA's Forecast
Apr-08-15 07:48PM  Rare Death Linked To Ingredient, But Not Biogen Drug at Investor's Business Daily
06:23PM  Inovio Pharmaceuticals, Zynga Among Big Movers In Wednesday's After-Hours Session
05:00PM  Patient Dies Using Drug With Ingredients Like Biogens Tecfidera at Bloomberg
01:20PM  Biosimilar drugs: spot the difference at Financial Times
10:10AM  Stock Market News for April 08, 2015 - Market News
07:08AM  Alzheon's CEO says he can beat Biogen with the worlds first Alzheimers drug at bizjournals.com
Apr-07-15 10:18PM  Its That Time Again: Q1 Earnings Preview
07:42PM  Apple: A Top Mutual Fund Manager's Concerns at Investor's Business Daily
06:32PM  Investing in brain health: Ex-NFL star at CNBC
07:30AM  Biogen Data at AAN Annual Meeting Underscore Commitment to Advancing Patient Care in Neurology Business Wire
Apr-06-15 05:20PM  Biotech Stocks Still Feeling Healthy Despite Bubble Talk at TheStreet
Apr-05-15 12:45PM  Man in custody after human remains found in bag near MIT campus
Apr-03-15 05:00AM  'Fast Money' Recap: Expect Continued Oil Price Pressure With Iran Deal at TheStreet
Apr-02-15 05:30PM  Biotech run near an end?
04:56PM  On Apple, is it time to temper expectations? at MarketWatch
01:55PM  BioMed scores against rival Alexandria with new lease to Biogen at bizjournals.com
09:30AM  The Zacks Analyst Blog Highlights: Horizon Pharma, Hyperion Therapeutics, Conatus, Amgen and Biogen - Press Releases
07:31AM  How RBC Capital Called A 50% Gain In This Biotech Stock
Apr-01-15 05:42PM  Health Stocks Lead The Pack In Q1; Are They Fading? at Investor's Business Daily
04:01PM  Biogen to Report First Quarter 2015 Financial Results on April 24, 2015 Business Wire
03:12PM  Biotech Stock Roundup: Horizon to Buy Hyperion, Conatus Up on Liver Disease Data - Analyst Blog
11:03AM  Biogen Idec: Survey Says at Barrons.com
09:20AM  Barclays Raises Biogen Forecasts After Physician Survey
06:01AM  Soaring biotech stocks are looking a bit sickly at MarketWatch
Mar-31-15 03:49PM  Biogen's Biosimilar Version of Remicade Under EU Review - Analyst Blog
02:45PM  On the move: New hires and job transitions in the local life science industry at bizjournals.com
11:57AM  Health-care hedge fund Orbimed's top picks at MarketWatch
10:54AM  Biotech: Why It's Not a Bubble at Barrons.com
Mar-30-15 06:55PM  Cramer: The best places for you to put new money at CNBC
06:09PM  Biogen/AbbVie's MS Drug Zinbryta Under Review in the EU - Analyst Blog
06:00PM  Making Money With Charles Payne: 03/30/15 at Fox Business
03:07PM  Why Gilead Stock Could Rise
02:20PM  Retail Investors: Buyers in all Ten Sectors Last Week
11:31AM  Bulls, Bears Squaring Off At Biogen
11:12AM  Teva, Horizon Snap Up Orphan-Disease Drugs at Investor's Business Daily
02:00AM  Biogen Announces EMA Validation of Marketing Authorization Application for SB2, a Biosimilar Candidate for Infliximab Business Wire
Mar-27-15 07:26PM  Biotech bubble popped, time to buy again? at Fortune
06:40PM  Cramer: 4 horsemen of biotech & semis are back at CNBC
04:18PM  BIOGEN INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year
03:14PM  Biotech bubble may just be an optical illusion at MarketWatch
01:30PM  Here's everything you need to know about the biotech bubble at bizjournals.com
01:16PM  Which 4 Big Drugmakers Have Rising Estimates? at Investor's Business Daily
11:19AM  The biotech sector looks an awful lot like a bubble
10:37AM  Biotech: 'Unprecedented Times,' Not a Bubble at Barrons.com
08:35AM  RBC Has 4 Biotech Stocks to Buy After Massive Pullback at 24/7 Wall St.
07:00AM  European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA (Daclizumab High-Yield Process) for Treatment of MS Business Wire
Mar-26-15 02:12PM  Biotech Battering Renews Bubble Debate Over Sector's Pricey Stocks at Forbes
12:53PM  Biogen Shares Set for Another Pullback at Barrons.com
12:32PM  What You Need To Know About This Boom: Our Q&A With A Biotech Expert
12:12PM  Biotech Stock Selloff: Is It Justified? at Investor's Business Daily
12:02PM  Healthcare Hedge Fund Orbimeds Top Picks and New Move at Insider Monkey
10:09AM  "It's a boom, not a bubble" -- except in biotech, Lindzon says
09:47AM  The Biotech Selloff: It's Déjà Vu All Over Again at Barrons.com
Biogen Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurological, autoimmune, and hematologic disorders in the United States and internationally. It provides AVONEX to treat relapsing multiple sclerosis (MS); TYSABRI to treat relapsing forms of MS and Crohn's disease; PLEGRIDY to treat relapsing MS; TECFIDERA to treat MS; FAMPYRA to improve walking in adult patients with MS; ALPROLIX to treat hemophilia B; ELOCTATE to treat hemophilia A; RITUXAN for treating non-Hodgkin's lymphoma, rheumatoid arthritis, and chronic lymphocytic leukemia (CLL), as well as two forms of ANCA-associated vasculitis; GAZYVA for the treatment of patients with previously untreated CLL; and FUMADERM to treat severe plaque psoriasis in adult patients. The company's products that completed Phase III clinical trials comprise ZINBRYTA, a monoclonal antibody in relapsing MS. Its products under Phase III clinical trials consist of TYSABRI for secondary progressive MS and spinal muscular atrophy; ISIS SMN for spinal muscular atrophy; and GAZYVA for non-Hodgkin's lymphoma. The company's Phase II clinical trial products include Anti-LINGO for optic neuritis and MS; Neublastin for neuropathic pain; TYSABRI for optic neuritis; ANTI-TWAEK for lupus nephritis; BAN2401 and E2609 for Alzheimer's disease; and GAZYVA for lupus nephritis, as well as Phase IIa clinical trial products include STX-100 for idiopathic pulmonary fibrosis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; ISIS DMPK for myotonic dystrophy; BIIB061 for MS; and Anti-BDCA2 for systemic lupus erythematosus, as well as Phase Ib clinical trial products include BIIB037 for Alzheimer's disease and Anti-C for systemic lupus erythematosus. The company was formerly known as Biogen Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerApr 02Option Exercise0.0097502,134Apr 03 04:24 PM
SCANGOS GEORGE AChief Executive OfficerApr 01Sale423.201,362576,39843,814Apr 02 04:29 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 27Sale430.12430184,9528,574Mar 30 04:13 PM
Cox JohnEVP Pharmaceutical Oper & TechMar 25Option Exercise65.855,066333,57137,577Mar 26 04:31 PM
Cox JohnEVP Pharmaceutical Oper & TechMar 25Sale449.0612,0105,393,21125,567Mar 26 04:31 PM
Rowinsky Eric KDirectorMar 20Option Exercise59.8211,667697,92022,977Mar 23 04:33 PM
Rowinsky Eric KDirectorMar 20Sale475.0011,6675,541,82511,310Mar 23 04:33 PM
Rowinsky Eric KDirectorMar 19Option Exercise59.822,333139,56013,643Mar 20 05:03 PM
Rowinsky Eric KDirectorMar 19Sale436.142,3331,017,50811,310Mar 20 05:03 PM
Rowinsky Eric KDirectorMar 17Option Exercise59.824,667279,18015,977Mar 18 05:03 PM
Rowinsky Eric KDirectorMar 17Sale425.454,6671,985,58911,310Mar 18 05:03 PM
DiPietro KennethEVP Human ResourcesMar 16Sale415.46803333,6140Mar 17 08:10 PM
SCANGOS GEORGE AChief Executive OfficerMar 13Sale412.69537221,61345,176Mar 16 08:39 PM
PANGIA ROBERT WDirectorMar 10Option Exercise47.713,625172,95417,998Mar 11 04:13 PM
SHERWIN STEPHEN ADirectorMar 10Option Exercise59.826,000358,92010,150Mar 11 04:17 PM
SHERWIN STEPHEN ADirectorMar 10Sale409.676,0002,458,0204,150Mar 11 04:17 PM
PANGIA ROBERT WDirectorMar 10Sale413.403,6251,498,57814,873Mar 11 04:13 PM
Rowinsky Eric KDirectorMar 09Option Exercise59.824,666279,12015,976Mar 11 04:15 PM
Rowinsky Eric KDirectorMar 09Sale417.234,6661,946,79511,310Mar 11 04:15 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerMar 02Sale409.493,1741,299,7159,004Mar 03 04:44 PM
SCANGOS GEORGE AChief Executive OfficerMar 02Sale410.67825338,80345,713Mar 03 04:39 PM
SCANGOS GEORGE AChief Executive OfficerFeb 19Sale401.04537215,35846,538Feb 20 04:28 PM
SCANGOS GEORGE AChief Executive OfficerFeb 17Sale389.11825321,01647,075Feb 18 04:45 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 17Sale389.112,128828,0264,321Feb 18 04:41 PM
DiPietro KennethEVP Human ResourcesFeb 17Sale389.111,188462,263803Feb 18 04:37 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 17Sale389.11418162,64815,004Feb 18 04:36 PM
SCANGOS GEORGE AChief Executive OfficerFeb 12Option Exercise0.0015,599045,547Feb 17 09:32 PM
COVINO GREGORY FVP, Chief Accounting OfficerFeb 12Option Exercise0.0047101,450Feb 17 09:16 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 12Option Exercise0.003,63407,152Feb 17 08:54 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerFeb 12Option Exercise0.001,20101,318Feb 17 08:50 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 12Option Exercise0.001,605015,805Feb 17 08:47 PM
Clancy Paul JExecutive VP and CFOFeb 12Option Exercise0.004,299022,960Feb 17 08:44 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,738033,214Feb 17 08:40 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 12Option Exercise0.005,200016,481Feb 17 08:37 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 12Option Exercise0.003,769028,634Feb 17 08:34 PM
DiPietro KennethEVP Human ResourcesFeb 12Option Exercise0.003,76402,706Feb 17 08:30 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 12Option Exercise0.003,60108,771Feb 17 08:26 PM
SCANGOS GEORGE AChief Executive OfficerFeb 10Option Exercise0.0018,833043,148Feb 11 04:25 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 10Sale398.111,143455,03914,574Feb 11 04:26 PM
Clancy Paul JExecutive VP and CFOFeb 09Option Exercise0.004,691022,194Feb 10 05:06 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 09Option Exercise0.004,691032,744Feb 10 05:07 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 09Option Exercise0.001,82407,088Feb 10 05:08 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Option Exercise0.001,824016,398Feb 10 05:11 PM
SCANGOS GEORGE AChief Executive OfficerFeb 09Option Exercise0.0011,270029,255Feb 11 04:25 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 09Option Exercise0.003,909027,716Feb 10 05:12 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 09Sale398.05856340,73114,574Feb 10 05:11 PM
ALEXANDER SUSAN HEVP, Chief Legal OfficerFeb 08Option Exercise0.002,498024,625Feb 10 05:12 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 08Option Exercise0.003,468014,542Feb 10 05:14 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerFeb 08Option Exercise0.001,277015,851Feb 10 05:11 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 08Option Exercise0.002,70505,802Feb 10 05:10 PM
Kingsley Stuart AEVP, Global Comm. OperationsFeb 08Option Exercise0.002,63606,147Feb 10 05:08 PM
Cox JohnEVP Pharmaceutical Oper & TechFeb 08Option Exercise0.004,023029,590Feb 10 05:07 PM
Clancy Paul JExecutive VP and CFOFeb 08Option Exercise0.003,191018,646Feb 10 05:06 PM
DiPietro KennethEVP Human ResourcesFeb 02Sale389.031,656644,2340Feb 03 06:35 PM
DiPietro KennethEVP Human ResourcesFeb 01Option Exercise0.002,46302,463Feb 02 07:46 PM
WILLIAMS DOUGLAS EEVP Research & DevelopmentFeb 01Option Exercise0.005,157013,133Feb 02 07:43 PM
Holtzman Steven HEVP Corporate DevelopmentFeb 01Option Exercise0.005,15705,157Feb 02 07:40 PM
Artavanis-Tsakonas SpyridonSVP, Chief Scientific OfficerDec 15Sale346.501,981686,417352Dec 16 04:36 PM
Sandrock AlfredGrp SVP, Chief Medical OfficerDec 04Sale345.88440152,18714,574Dec 05 05:20 PM
Holtzman Steven HEVP Corporate DevelopmentDec 02Sale335.651,749587,0520Dec 03 04:32 PM
Holtzman Steven HEVP Corporate DevelopmentNov 11Sale330.001,750577,5001,749Nov 12 04:24 PM
SCANGOS GEORGE AChief Executive OfficerNov 03Sale320.781,128361,84017,985Nov 04 04:18 PM
SCANGOS GEORGE AChief Executive OfficerOct 01Sale330.971,127373,00319,113Oct 02 04:44 PM
Holtzman Steven HEVP Corporate DevelopmentOct 01Sale330.971,750579,1983,499Oct 02 04:42 PM
SCANGOS GEORGE AChief Executive OfficerSep 02Sale345.471,128389,69020,240Sep 04 04:15 PM
SCANGOS GEORGE AChief Executive OfficerAug 01Sale332.931,128375,54521,368Aug 04 04:43 PM
SCANGOS GEORGE AChief Executive OfficerJul 16Sale312.3712,3163,847,14922,496Jul 18 05:59 PM
SCANGOS GEORGE AChief Executive OfficerJul 15Option Exercise0.0021,339044,874Jul 17 04:45 PM
Posner Brian SDirectorJun 20Sale315.00605190,5756,000Jun 23 04:37 PM
Posner Brian SDirectorJun 13Sale310.50700217,3506,605Jun 16 04:37 PM
SCANGOS GEORGE AChief Executive OfficerJun 02Sale318.93484154,36223,535Jun 03 04:29 PM
Holtzman Steven HEVP Corporate DevelopmentMay 19Sale289.151,221353,0525,749May 20 04:16 PM
COVINO GREGORY FVP, Chief Accounting OfficerMay 01Option Exercise286.7534799,5021,029May 02 04:20 PM
SCANGOS GEORGE AChief Executive OfficerMay 01Sale285.562,123606,24124,019May 02 04:22 PM